Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFIT: HR20013 (Fosrolapitant/Palonosetron) for CINV Prevention
NCT05509634Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosrolapitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Complete response during the overall phase after the start of the first cisplatin administration. Started Sep 2022; status: completed.
02
Drugs
fosrolapitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05509634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509634.